Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2526)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5696)
  2. Department of Medicine (5686)
  3. GSK Faculty (1659)
  4. Human Oncology and Pathogenesis Program (1158)
  5. Department of Pathology and Laboratory Medicine (1130)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (786)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (204)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (690)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5696)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa)
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Knezevic, A.; Bambury, R. M.; Hatzoglou, V.; Autio, K. A.; Abida, W.; Gopalan, A.; Fine, S.; Danila, D. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
    Meeting Abstract

    Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer
    Meeting Abstract

    Mazzu, Y. Z.; Chakraborty, G.; Yoshikawa, Y.; Nandakuma, S.; Armenia, J.; Jehane, L. E.; Lee, G. S. M.; Mucci, L.; Kantoff, P. W.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214
    Meeting Abstract

    McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Di Natale, R. G.; Chowell, D.; Makarov, V.; Redzematovic, A.; Murray, S. J.; Carlo, M. I.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Rates of occult brain metastases in patients (pts) with advanced renal cell carcinoma (RCC): A cohort study from patients treated across 22 clinical trials
    Meeting Abstract

    Kotecha, R.; Redzematovic, A.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Gupta, S.; Sonpavde, G.; Grivas, P.; Apolo, A. B.; Plimack, E. R.; Flaig, T. W.; Hahn, N. M.; Balar, A. V.; Bajorin, D. F.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (10) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts)
    Meeting Abstract

    Ged, Y.; Chaim, J.; Knezevic, A.; Carlo, M. I.; Foster, A.; Feldman, D. R.; Teo, M. Y.; Riaz, N.; Lee, C. H.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Hakimi, A. A.; Ged, Y.; Flynn, J.; Hoen, D. R.; Di Natale, R. G.; Blum, K. A.; Makarov, V.; Kuo, F.; Carlo, M. I.; Lee, C. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save